Replimune REPL
NASDAQ REPL
$15.04 -0.25 (-1.64%)
As of: Sep 4, 2026 · 3:59 PM EDT

Replimune (REPL) Cash from Financing Activities (2018 - 2026)

Replimune (REPL) posted Cash from Financing Activities of $55.7 million for Q1 2026, up 432.74% sequentially from $10.5 million in Q4 2025, and up 42279.55% YoY from N/an in Q1 2025.

Analysis

Replimune (REPL) Cash from Financing Activities (2018 - 2026) Analysis & Trends

Replimune has reported Cash from Financing Activities for 9 years, with the latest figure at $55.7 million in Q1 2026.

  • Quarterly Cash from Financing Activities rose 42279.55% year-over-year to $55.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.3 million (down 73.73% YoY) and the FY2026 annual result came in at $66.3 million, down 73.73% from the prior year.
  • Cash from Financing Activities advanced to $55.7 million in Q1 2026 per REPL's latest filing, from $10.5 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $271.4 million in Q4 2022 and troughed at -$158000.0 in Q2 2025.
  • A 5-year average of $38.0 million and a median of $1.1 million in 2023 frame the typical range for Cash from Financing Activities.
  • The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities plunged 121.45% in 2023, then surged 42279.55% in 2026.
  • Over 5 years, Cash from Financing Activities stood at $271.4 million in 2022, then sank by 94.52% to $14.9 million in 2023, then soared by 948.62% to $155.9 million in 2024, then tumbled by 93.3% to $10.5 million in 2025, then soared by 432.74% to $55.7 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered $55.7 million, $10.5 million, and $324000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Replimune 1.46 Bn 1.46 Bn - 800,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 800,000.00
Mar 31, 2026 55.68 Mn
Dec 31, 2025 10.45 Mn
Sep 30, 2025 324,000.00
Jun 30, 2025 -158,000.00
Mar 31, 2025 -132,000.00
Dec 31, 2024 155.93 Mn
Sep 30, 2024 -39,000.00
Jun 30, 2024 96.64 Mn
Mar 31, 2024 -130,000.00
Dec 31, 2023 14.87 Mn
Sep 30, 2023 438,000.00
Jun 30, 2023 1.11 Mn
Mar 31, 2023 -77,000.00
Dec 31, 2022 271.44 Mn
Sep 30, 2022 7.42 Mn
Jun 30, 2022 32.52 Mn
Mar 31, 2022 359,000.00
Dec 31, 2021 3.97 Mn
Sep 30, 2021 1.15 Mn